No Detail Found!

Effects of pregabalin vs gabapentin on pain intensity in patients with chronic sciatica in bmch hospital quetta effects of pregabalin vs gabapentin on pain intensity in patients with chronic sciatica in bmch hospital quetta

Author(s)
Muhammad Essa Department of Neurology, Bolan Medical Complex Hospital, Quetta, Pakistan
Amanullah Kakar Department of Neurology, Bolan Medical Complex Hospital, Quetta, Pakistan
Noor Ahmed Khosa Department of Neurology, Bolan Medical Complex Hospital, Quetta, Pakistan
Muhammad Saleem Department of Neurology, Bolan Medical Complex Hospital, Quetta, Pakistan
Noman Ul Haq Department of Pharmacy Practice, University of Balochistan, Quetta, Pakistan
Ahsan Ul Haq Zarkoon Department of Neurology, Bolan Medical Complex Hospital, Quetta, Pakistan
Anjum Farooq Department of Neurology, Bolan Medical Complex Hospital, Quetta, Pakistan
Wazir Akber Department of Neurology, Bolan Medical Complex Hospital, Quetta, Pakistan
Abstract
Background: Sciatica is a challenging neuropathic pain disorder, and it is extremely difficult to treat it adequately. This trial aims to assess the effectiveness of gabapentin (GBP) and pregabalin (PGB) in treating sciatic pain. Objective: To evaluate and compare the effectiveness of pregabalin (PGB) and gabapentin (GBP) in treating persistent sciatica. Materials and methods: The study design was a prospective, double-blind, single-center, double-dummy randomized, cross-over in patients with chronic sciatica. The study was conducted at the Department of Neurology Bolan Medical Complex Hospital, Quetta. The study included 67 participants to explore the efficacy of GBP and PGB in sciatic pain. The Quebec Back Pain Scale and VAS were used to measure the efficacy of gabapentin (GBP) and pregabalin (PGB) in treating chronic sciatica adverse events, concurrent drug profiles, and demographic factors were evaluated. Results: In this randomized control trial (n = 67), there was a significant improvement in functionality (GBP: Quebec Back Pain Scale 60.61 to 35.21, p <.003; PGB: Quebec Back Pain Scale 60.64 to 37.03, p <.001) and a significant reduction in pain (GBP: VAS 7.77 to 3.22, p <.012; PGB: VAS 7.82 to 3.46, p <.012). Gabapentin was found to be more effective (VAS difference: 3.22 vs. 3.46, p =.003; improvement on the Quebec Back Pain Scale: 35.21 vs. 37.03, p =.017). Adverse effects ranged; gabapentin showed increased vertigo/dizziness (9.68% vs. 6.45%) and pregabalin showed higher drowsiness (79.03% vs. 27.42%) Conclusion: For persistent sciatica, gabapentin is a better option because it works better at reducing pain intensity. These results offer clinicians useful information for customizing neuropathic pain management approaches.
Publication Details
Page(s) 541-550
Published Journal: Pak-Euro Journal of Medical and Life Sciences, Volume: 6, Issue: 4, Year: 2023

Request the full text from PASTIC

Keywords
Pregabalin, Adverse events, Gabapentin, pain reduction, Randomized trial, Chronic sciatica, Functional improvement
0

Citations

0

Downloads

40

Views